Statistik Asas
| LEI | 549300U6XU1GKTTNHD15 |
| CIK | 822370 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Mynd.ai, Inc. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss |
|
| August 14, 2025 |
Future Receivables Sale and Purchase Agreement with iFund Experts Exhibit 10.2 Future Receivables Sale and Purchase Agreement Requirements: • Please review and verify your bank account information where indicated, or if it is missing, fill in the correct information on page 17of the agreement. • MAKE SURE ALL THE REFERENCES ARE FILLED OUT ON THE PAGE 20 • Please return: - CC Processing Statement or A/R Report - Proof of business that has the company EIN for conf |
|
| August 14, 2025 |
Agreement for the Purchase and Sale of Future Receipts with Agile Capital Exhibit 10.1 Agreement for the Purchase and Sale of Future Receipts Seller's Legal Name: EMMAUS MEDICAL, INC. D/B/A: EMMAUS MEDICAL Form of Business Entity: [ ] Corporation; [ ] Limited Liability Company; [ ] Partnership; [ ] Limited Partnership; [ ] Limited Liability Partnership; [ ] Sole Proprietorship; [ ] Other: Street Address: 21250 HAWTHORNE BLVD STE 800 City: TORRANCE State: CA Zip: 90503 M |
|
| August 14, 2025 |
Emmaus Life Sciences Reports Quarterly Financial Results Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, August 14, 2025 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2025. Highlights “We experienced a 48% |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, IN |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissio |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, I |
|
| May 15, 2025 |
Emmaus Life Sciences Reports Quarterly Financial Results Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, May 15, 2025 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2025. Highlights “We are pleased to report that |
|
| May 15, 2025 |
Agreement for the Purchase and Sale of Future Receipts with Agile Capital Exhibit 10.1 Agreement for the Purchase and Sale of Future Receipts Seller's Legal Name: EMMAUS MEDICAL, INC. D/B/A: EMMAUS MEDICAL Form of Business Entity: [ ] Corporation; [ ] Limited Liability Company; [ ] Partnership; [ ] Limited Partnership; [ ] Limited Liability Partnership; [ ] Sole Proprietorship; [ ] Other: Street Address: 21250 HAWTHORNE BLVD STE 800 City: TORRANCE State: CA Zip: 90503 M |
|
| May 6, 2025 |
Letter dated May 5, 2025 from Marcum LLP to the Securities and Exchange Commission Exhibit 16.1 May 5, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Emmaus Life Sciences, Inc. under Item 4.01 of its Form 8- K dated May 5, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Emmaus Life Sciences, Inc. conta |
|
| May 6, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2025 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission |
|
| April 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi |
|
| April 14, 2025 |
Emmaus Life Sciences Reports 2024 Financial Results Exhibit 99.1 Emmaus Life Sciences Reports 2024 Financial Results Torrance CA, April 14, 2025 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2024. Recent Highlights “We experienced a decline of nea |
|
| April 14, 2025 |
Agreement for the Purchase and Sale of Future Receipts with Agile Capital dated December 2, 2024 Exhibit 10.48 Agreement for the Purchase and Sale of Future Receipts Seller's Legal Name: EMMAUS MEDICAL, INC. D/B/A: EMMAUS MEDICAL Form of Business Entity: [ ] Corporation; [ ] Limited Liability Company; [ ] Partnership; [ ] Limited Partnership; [ ] Limited Liability Partnership; [ ] Sole Proprietorship; [ ] Other: Street Address: 21250 HAWTHORNE BLVD STE 800 City: TORRANCE State: CA Zip: 90503 |
|
| April 14, 2025 |
Exhibit 21.1 List of Registrant’s Subsidiaries Name Place of incorporation Emmaus Medical, Inc. Delaware Emmaus Medical Japan, Inc. Japan Newfield Nutrition Corp. Delaware Emmaus Medical Europe, Ltd. United Kingdom Emmaus Medical Europe, Ltd. Ireland Emmaus Life Sciences, Co. Ltd Korea |
|
| April 14, 2025 |
Exhibit 10.9 FOURTH AMENDMENT TO OFFICE LEASE AGREEMENT This FOURTH AMENDMENT TO OFFICE LEASE AGREEMENT (this "Fourth Amendment") is made effective as of November 20, 2024 (the "Effective Date"), by and between RREF II PACIFIC CENTER LLC, a Delaware limited liability company ("Landlord"), and EMMAUS LIFE SCIENCES, INC., a Delaware corporation ("Tenant"). Landlord and Tenant are each sometimes refe |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K e UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmaus Life Sciences, I |
|
| April 1, 2025 |
SEC File Number: 001-35527 CUSIP Number: 29137T101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCE |
|
| November 19, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| November 19, 2024 |
Emmaus Life Sciences Reports Improved Quarterly Financial Results Exhibit 99.1 Emmaus Life Sciences Reports Improved Quarterly Financial Results Torrance CA, November 19, 2024 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2024. Highlights “We |
|
| November 19, 2024 |
Agreement for the Purchase and Sale of Future Receipts with Agile Capital Agreement for the Purchase and Sale of Future Receipts Exhibit 10.1 Seller's Legal Name: EMMAUS MEDICAL, INC. D/B/A: EMMAUS MEDICAL Form of Business Entity: [ ] Corporation; [ ] Limited Liability Company; [ ] Partnership; [ ] Limited Partnership; [ ] Limited Liability Partnership; [ ] Sole Proprietorship; [ ] Other: Street Address: 21250 HAWTHORNE BLVD STE 800 City: TORRANCE State: CA Zip: 90503 M |
|
| November 14, 2024 |
SEC File Number: 001-35527 CUSIP Number: 29137T101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 6, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis |
|
| October 25, 2024 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Comm |
|
| September 10, 2024 |
Promissory Note dated March 15, 2024 Exhibit 10.4 THIS PROMISSORY NOTE HAS NOT BEEN AND WILL NOT BE REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES AC |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, I |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, IN |
|
| September 10, 2024 |
Emmaus Life Sciences Reports Quarterly Financial Results Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, September 10, 2024 - Emmaus Life Sciences, Inc. (OTC Markets: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year quarters ended March 31 and June 30, 2024. Recent Highlights |
|
| September 10, 2024 |
September 10, 2024 Letter of Baker Tilly US, LLP to the Securities and Exchange Commission Exhibit 16.1 Baker Tilly US, LLP 18500 Von Karman Ave; 10th Fl. Irvine, CA 92612 United States of America T: +1 (949) 222 2999 F: +1 (949) 222 2989 bakertilly.com September 10, 2024 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentlemen: We are the former independent registered public accounting firm for Emmaus Life Sciences, Inc. (the “Company”). We hav |
|
| September 10, 2024 |
Agreement for the Purchase and Sale of Future Receipts with Agile Capital Exhibit 10.1 Agreement for the Purchase and Sale of Future Receipts Seller's Legal Name: EMMAUS MEDICAL, INC. D/B/A:EMMAUS MEDICAL Form of Business Entity: [ ] Corporation; [ ] Limited Liability Company; [ ] Partnership; [ ] Limited Partnership; [ ] Limited Liability Partnership; [ ] Sole Proprietorship; [ ] Other: Street Address: 21250 HAWTHORNE BLVD STE 800 City: TORRANCE State: CA Zip: 90503 Ma |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| August 15, 2024 |
SEC File Number: 001-35527 CUSIP Number: 29137T101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissio |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission |
|
| July 3, 2024 |
Promissory Note dated December 1, 2023 issued by registrant to Wei Peu Zen Exhibit 10.41 THIS PROMISSORY NOTE HAS NOT BEEN AND WILL NOT BE REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES A |
|
| July 3, 2024 |
Exhibit 10.20 EMMAUS LIFE SCIENCES, INC. AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 1 to Convertible Promissory Note (this "Amendment") is made and entered into as of the date of the last signature hereto by and between Emmaus Life Sciences, Inc., a Delaware corporation ("Borrower" or the "Company"), and the undersigned holder (the "Holder") of the Convertible Promissory Not |
|
| July 3, 2024 |
Emmaus Life Sciences Reports 2023 Financial Results Exhibit 99.1 Emmaus Life Sciences Reports 2023 Financial Results Torrance CA, July 3, 2024 - Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2023. Recent Highlights “We are pleased to report that we |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K e UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmaus Life Sciences, I |
|
| July 3, 2024 |
Exhibit 21.1 List of Registrant’s Subsidiaries Name Place of incorporation Emmaus Medical, Inc. Delaware Emmaus Medical Japan, Inc. Japan Newfield Nutrition Corp. Delaware Emmaus Medical Europe, Ltd. United Kingdom Emmaus Medical Europe, Ltd. Ireland Emmaus Life Sciences, Co. Ltd Korea |
|
| July 3, 2024 |
Exhibit 10.23 EMMAUS LIFE SCIENCES, INC. AMENDMENT NO. 4 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 4 to Convertible Promissory Note (this "Amendment") is made and entered into as of June 15, 2023 by and between EMI Holding, Inc., a Delaware corporation (formerly known as Emmaus Life Sciences, Inc and herein "Borrower" or the "Company"), and the undersigned holder or its registered assigns |
|
| May 28, 2024 |
Amendment No. 1 to Amended and Restated By-Laws Exhibit 3.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED BY-LAWS OF EMMAUS LIFE SCIENCES, INC. The Amended and Restated By-laws of Emmaus Life Sciences, Inc. (formerly CNS Response, Inc. and MYnd Analytics, Inc.”) are hereby amended to add thereto a new Article VIII as follows: “ARTICLE VIII CERTAIN LITIGATION MATTERS Section 8.01 Delaware Forum. Unless the Corporation consents in writing to the select |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission |
|
| April 1, 2024 |
SEC File Number: 001-35527 CUSIP Number: 29137T101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| February 26, 2024 |
Exchange Agreement dated as of February 21, 2024 Exhibit 10.1 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this “Agreement”), dated as of February 21, 2024, is made and entered into by and between Emmaus Life Sciences, Inc., a Delaware corporation, with offices located at 21250 Hawthorne Boulevard, Suite 800, Torrance, CA 90503 (the “Company”), and the individuals that are signatories to this Agreement (the “Investors”), with reference to the fol |
|
| February 26, 2024 |
Form of Joinder Agreement and Amendment to Transfer Restriction and Voting Agreement Exhibit 10.2 THIS JOINDER AREEMENT AND AMENDMENT TO TRANSFER RESTRICTION AND VOTING AGREEMENT (this “Agreement”) is made with reference to the TRANSFER RESTRICTION AND VOTING Agreement (the “Voting Agreement”) made and entered into as of February 8, 2021 by and among between Emmaus Life Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the purchaser signature |
|
| February 26, 2024 |
Form of Convertible Promissory Note Due February 24, 2025 Exhibit 4.1 NEITHER THIS CONVERTIBLE PROMISSORY NOTE NOR THE SECURITIES ISSUABLE HEREUNDER HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRA |
|
| December 22, 2023 |
EMMA / Emmaus Life Sciences, Inc. / Lim Seah H. - SCHEDULE 13G Passive Investment SC 13G 1 ea190621-13gseahemmaus.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* EMMAUS LIFE SCIENCES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 29137T101 (CUSIP Nu |
|
| December 20, 2023 |
Exchange Agreement dated as of December 15, 2023 Exhibit 10.1 EXCHANGE AGREEMENT EXCHANGE AGREEMENT (this “Agreement”), dated as of December 15, 2023, by and between Emmaus Life Sciences, Inc., a Delaware corporation, with offices located at 21250 Hawthorne Boulevard, Suite 800, Torrance, CA 90503 (the “Company”), and the other signatories to this Agreement (the “Investors”), with reference to the following facts. WHEREAS: A. Each of the Investo |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| November 14, 2023 |
Emmaus Life Sciences Reports Q3 2023 Financial Results Exhibit 99.1 Emmaus Life Sciences Reports Q3 2023 Financial Results Torrance CA, November 14, 2023 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023. Recent Highlights “We expe |
|
| November 14, 2023 |
Promissory Note dated September 28, 2023 DocuSign Envelope ID: C82640C4-3CD9-4A31-B20D-D7F478391F44 Exhibit 10.3 ** PLEASE READ CAREFULLY ** Dear Borrower, we are glad to welcome you to our unique financing program. The program will go into effect immediately after you return a signed agreement and will continue to be in effect until we receive the full loan repayment Amount according to this agreement. After we receive the full agreed u |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| November 14, 2023 |
Convertible Promissory Note dated September 5, 2023 Exhibit 4.1 NEITHER THIS SECURITY NOR ANY SECURITY INTO WHICH IT IS CONVERTIBLE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE PLEDGED, TRANSFERRED, ASSIGNED, OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR PURS |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCE |
|
| November 14, 2023 |
Promissory Note dated July 19, 2023 Exhibit 10.1 OFFER SUMMARY – REVENUE PURCHASE AGREEMENT Funding Provided $581,815.00 This is how much funding AKF INC DBA FundKite will provide. Due to deductions or payments to others, the total funds that will be provided to you directly is $299,930.48. For more information on what amounts will be deducted, please review the attached document “Itemization of Amount Financed." The total funds pro |
|
| November 14, 2023 |
Promissory Note dated July 19, 2023 Exhibit 10.2 OFFER SUMMARY – REVENUE BASED FINANCING Funding Provided $582,000.00 This is how much funding CLOUDFUND LLC will provide. Due to deductions or payments to others, the total funds that will be provided to you directly is $275,657.34. For more information on what amounts will be deducted, please review the attached document “Itemization of Amount Financed.” The total funds provided to y |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss |
|
| August 23, 2023 |
Exhibit 99.1 Emmaus Life Sciences Reports Management Changes Principal Inventor of Endari® (L-glutamine oral powder) and Long-time Chairman and Chief Executive Officer Free to Purse New Projects Company Appoints Interim Co-Presidents to Focus on Core Business Torrance CA, August 23, 2023 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the trea |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss |
|
| August 14, 2023 |
Promissory Note dated June 14, 2023 Exhibit 10.4 15 America Ave Suite 303, Lakewood, NJ 08701 (646) 437-6010 STANDARD MERCHANT CASH ADVANCE AGREEMENT This is an Agreement dated 06/14/2023 by and between Slate Advance (“SA2”) and each merchant listed below (“Merchant”). Merchant’s Legal Name: EMMAUS MEDICAL, INC. and all entities listed on addendum - "MERCHANT LIST" D/B/A: EMMAUS MEDICAL Fed ID #: 87-0419387 Type of Entity: Corporati |
|
| August 14, 2023 |
Exhibit 99.1 Emmaus Life Sciences Reports Q2 2023 Financial Results Record Net Revenues Contributed to Income from Operations Sixth Straight Quarterly Increase in Net Revenues Torrance CA, August 14, 2023 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results |
|
| August 14, 2023 |
Promissory Note dated April 24, 2023 Exhibit 10.1 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: US$1,830,000 Loan Date: 04/24/2023 Currency: US dollars Term: Due on demand Interest Rate: 11.0% per year Loan Due Date: Due on demand Interest Payment Period: Interest is payable annually Lender: Eastwind ltd. FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, IN |
|
| August 14, 2023 |
Promissory Note dated May 3, 2023 Exhibit 10.2 APEX FUNDING SOURCE LLC Tel: {646) 518-1521 Sale of Future Receipts Agreement Seller’s Legal Name EMMAUS MEDICAL, INC D/B/A EMMAUS LIFE SCIENCES Form of Business Entity and State of Incorporation Corporation CA Street Address 21250 HAWTHORNE BLVD STE 800 City, State TORRANCE, CA Zip 90503 Mailing Address City, State Zip Primary Contact Name YUTAKA NIIHARA Primary Contact Title Primary |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss |
|
| August 14, 2023 |
Promissory Note dated May 26, 2023 issued by registrant to Shigeru Matsuda. Exhibit 10.3 EMMAUS MEDICAL JAPAN Promissory Note Principal Amount: JPY90,792,400 Loan Date: 05/26/2023 Currency: Japanese Yen Term: Due on demand Interest Rate: 11.0% Loan Due Date: Due on demand Interest Payment Period: Interest is payable annually Lender: Shigeru Matsuda FOR VALUE RECEIVED, Emmaus Medical, Japan, a Japanese corporation, located at Bizmarks Akasaka 4F, 2-16-6, Ak |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, I |
|
| May 15, 2023 |
Promissory Note dated February 17, 2023 Exhibit 10.2 EMMAUS MEDICAL JAPAN Promissory Note Principal Amount: JPY124,058,736 Loan Date: 02/17/2023 Currency: Japanese Yen Term: 2 Years Interest Rate: 11.0% Loan Due Date: Due on demand Interest Payment Period: Interest is payable annually Lender: Shigeru Matsuda FOR VALUE RECEIVED, Emmaus Medical, Japan, a Japanese corporation, located at Bizmarks Akasaka 4F, 2-16-6, Akasaka, Minato-ku 107- |
|
| May 15, 2023 |
Promissory Note dated March 15, 2023 Exhibit 10.3 Congratulations, On Your Preliminary Offer! Dear EMMAUS MEDICAL, INC., This preliminary offer is based on a preliminary review and is not guaranty or commitment that FUNDKITE will consummate a transaction. Complete contracts and documentation described herein must be provided for underwriting review before FUNDKITE will enter into a transaction. Any misrepresentation in the application |
|
| May 15, 2023 |
Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update Exhibit 99.1 Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update Torrance CA, May 15, 2023 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2023. Recent Highligh |
|
| May 15, 2023 |
Promissory Note dated February 15, 2023 Exhibit 10.1 THIS PROMISSORY NOTE HAs NOT BEEN AND WILL NOT BE REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES AC |
|
| May 15, 2023 |
Promissory Note dated March 15, 2023 Exhibit 10.4 OFFER SUMMARY – REVENUE BASED FINANCING Funding Provided $487,058.00 This is how much funding CLOUDFUND LLC will provide. Due to deductions or payments to others, the total funds that will be provided to you directly is $487,058.00. For more information on what amounts will be deducted, please review the attached document “Itemization of Amount Financed.” The total funds provided to y |
|
| May 15, 2023 |
Promissory Note dated March 21, 2023 issued to Yutaka and Soomi Niihara Exhibit 10.6 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $127,000.00 Loan Date: March 21, 2023 Interest Rate: 10% per year Loan Due Date: On demand Lender: Yutaka & Soomi Niihara Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (“Borrower”), agrees to pay to Lender or his or |
|
| May 15, 2023 |
Common Stock Purchase Warrant dated January 12, 2023 Exhibit 4.4 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGI |
|
| May 15, 2023 |
Promissory Noted dated March 17, 2023 issued to Hope International Hospice, Inc. Exhibit 10.5 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $100,000.00 Loan Date: March 17, 2023 Interest Rate: 10% per year Loan Due Date: On demand Lender: Hope International Hospice, Inc. Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (“Borrower”), agrees to pay to Lender |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmaus Life Sciences, Inc |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi |
|
| March 31, 2023 |
Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update Exhibit 99.1 Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update Torrance CA, March 31, 2023 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported its results of operation for the year ended December 31, 2022 and an update on recent activities. Yutaka Niihara, M.D., M. |
|
| March 31, 2023 |
Policy on Insider Trading and Policy Regarding Special Trading Procedures Exhibit 19.1 EMMAUS LIFE SCIENCES, INC. POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES You should read this Policy address questions to the General Counsel of Emmaus Life Sciences, Inc. (formerly known as MYnd Analytics, Ince) and return the attached acknowledgement to Human Resources. Policy on Insider Trading Emmaus Life Sciences, Inc. including its subsidiaries and af |
|
| March 31, 2023 |
Promissory Note dated October 20, 2022 issued to Hope International Hospice, Inc. Exhibit 10.42 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $100,000.00 Loan Date: October 20, 2022 Interest Rate: 10% per year Loan Due Date: On demand Lender: Hope International Hospice, Inc. Address for Payment:20705 S. Western Ave., Suite 112 Torrance, CA 90501 FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Tor |
|
| March 31, 2023 |
Agreement for the Purchase and Sale of Future Receipts with Lendspark Exhibit 10.43 lendspark AGREEMENTFORTHEPURCHASEANDSALE OF FUTURE RECEIPTS ("AGREEMENT") AGREEMENT NO.: 2660 Requirements: - Sign and initial after every "X" on this contract - Fill in the correct account information on the addendum page Exhibit 10.43 Merchant Information: Business Name: EMMAUS LIFE SCIENCES, INC. Email: [email protected] Business Phone: 310-214-0065 Cell Phone: 310-4 |
|
| March 7, 2023 |
Convertible Promissory Note dated January 18, 2023 Exhibit 4.2 THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). NO SALE OR DISPOSITION MAY BE AFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN APPLICABLE EXEMPTION THEREFROM. THIS NOTE IS REGISTERED WITH THE COMPANY |
|
| March 7, 2023 |
Common Stock Purchase Warrant dated January 27, 2023 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE COMPANY SHALL HAVE RECEIVED AN OPINION |
|
| March 7, 2023 |
Form of Common Stock Purchase Warrants dated as of January 11, 2023 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE COMPANY SHALL HAVE RECEIVED AN OPINION |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis |
|
| February 21, 2023 |
SC 13D/A 1 ea173964-13da6niiharaemmaus.htm AMENDMENT NO. 6 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6) Emmaus Life Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29137T101 (CUSIP Number) Yutaka Niihara, M.D., M.P.H. 21250 Hawt |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2023 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis |
|
| December 12, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| November 15, 2022 |
Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update Exhibit 99.1 Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update Torrance CA, November 14, 2022 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its results of operations and financial condition as of and for the three and nine months ended September30, 2022 |
|
| November 14, 2022 |
Promissory Note dated August 16, 2022 issued to Yutaka and Soomi Niihara Exhibit 10.4 EXHIBIT A TO UNANIMOUS WRITTEN CONSENT EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $250,000.00Loan Date: August 16, 2022 Interest Rate: 10% per yearLoan Due Date: August 16, 2027 Lender: Yutaka and Soomi Niihara Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (? |
|
| November 14, 2022 |
Promissory Noted dated August 17, 2022 issued to Hope International Hospice, Inc. Exhibit 10.6 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $50,000.00Loan Date: August 17, 2022 Interest Rate: 10% per yearLoan Due Date: On demand Lender: Hope International Hospice, Inc. Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (?Borrower?), agrees to pay to Lender or |
|
| November 14, 2022 |
Warrant to Purchase Shares of Common Stock dated as of August 9, 2022 Exhibit 4.1 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGI |
|
| November 14, 2022 |
Promissory Note dated August 17, 2022 Exhibit 10.5 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $60,000.00Loan Date: August 17, 2022 Interest Rate: 10% per yearLoan Due Date: On demand Lender: Yutaka & Soomi Niihara Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (?Borrower?), agrees to pay to Lender or his or he |
|
| November 14, 2022 |
Promissory Note dated July 27, 2022 issued to Yutaka and Soomi Niihara Exhibit 10.1 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $402,000.00Loan Date: July 27, 2022 Interest Rate: 12% per yearLoan Due Date: July 31, 2027 Lender: Yutaka and Soomi Niihara Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (?Borrower?), agrees to pay to Lender or his |
|
| November 14, 2022 |
Promissory Note dated August 15, 2022 Exhibit 10.2 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $50,000.00Loan Date: August 15, 2022 Interest Rate: 10% per yearLoan Due Date: On demand Lender: Hope International Hospice, Inc. Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (?Borrower?), agrees to pay to Lender or |
|
| November 14, 2022 |
Promissory Note dated August 16, 2022 issued to Yutaka and Soomi Niihara Exhibit 10.3 EXHIBIT A TO UNANIMOUS WRITTEN CONSENT EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $1,668,751.00Loan Date: August 16, 2022 Interest Rate: 10% per yearLoan Due Date: August 16, 2027 Lender: Yutaka and Soomi Niihara Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 |
|
| November 14, 2022 |
Promissory Note dated September 16, 2022 Exhibit 10.7 THE SECURITIES ISSUABLE UNDER THIS PROMISSORY NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION ST |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q y UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIEN |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5) Emmaus Life Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29137T101 (CUSIP Number) Yutaka Niihara, M.D., M.P.H. 21250 Hawthorne Boulevard, Suite 800 Torrance, California 90503 (310) 214-0065 (Name, |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Comm |
|
| August 19, 2022 |
Exhibit 10.1 EXHIBIT A TO UNANIMOUS WRITTEN CONSENT EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $1,668,751.00 Loan Date: August 16, 2022 Interest Rate: 10% per year Loan Due Date: August 16, 2027 Lender: Yutaka and Soomi Niihara Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 9050 |
|
| August 19, 2022 |
Exhibit 10.3 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $50,000.00 Loan Date: August 15, 2022 Interest Rate: 10% per year Loan Due Date: On demand Lender: Hope International Hospice, Inc. Address for Payment:20705 S. Western Ave., Suite 112 Torrance, CA 90501 FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torran |
|
| August 19, 2022 |
Exhibit 10.2 EXHIBIT A TO UNANIMOUS WRITTEN CONSENT EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $250,000.00 Loan Date: August 16, 2022 Interest Rate: 10% per year Loan Due Date: August 16, 2027 Lender: Yutaka and Soomi Niihara Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss |
|
| August 15, 2022 |
Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update Exhibit 99.1 Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update Torrance CA, August 15, 2022 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update. Recent Highlights ? |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, IN |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi |
|
| August 10, 2022 |
Exhibit 99.1 August 4, 2022 VIA E-MAIL Dr. Yutaka Niihara CEO and Chairman of the Board Emmaus Life Sciences, Inc. 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 Re: Resignation Dear Yutaka: For the reasons that I have expressed to you in our recent communications, I feel that it is necessary that I resign from the Board and from my associated position on the Audit Committee. I hereby do so. |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmau |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission |
|
| June 10, 2022 |
Exhibit 99.1 June 8, 2022 Board of Directors Emmaus Life Sciences, Inc. 21250 Hawthorne Blvd, Suite 800 Torrance, CA 90503 Re: Request for Resignation from the Board Dear Board of Directors: As you are aware, Dr. Yutaka Niihara has requested repeatedly over the last few days that Lori Teranishi, Al Lui and Jane Pine Wood resign from the Board of Directors of Emmaus Life Sciences, Inc., ostensibly |
|
| May 13, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, I |
|
| May 13, 2022 |
Promissory Note dated March 31, 2022 issued to Wei Peu Zen Exhibit 10.3 EMMAUS LIFE SCIENCES, INC. Promissory Note THIS NOTE IS REGISTERED WITH THE COMPANY AS TO BOTH PRINCIPAL AND INTEREST AND, ACCORDINGLY, IS IN ?REGISTERED FORM? WITHIN THE MEANING OF SECTIONS 871(H) AND 881(C) OF THE UNITED STATES INTERNAL REVENUE CODE OF 1986, AS AMENDED. Principal Amount: $200,000.00Loan Date: March 31, 2022 Interest Rate: 10% per yearLoan Due Date: On demand Lender: |
|
| May 13, 2022 |
Form of Promissory Note issued to the persons indicated on Schedule A thereto Exhibit 10.2 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $Loan Date: Interest Rate: 10% per yearLoan Due Date: On demand Lender: Address for Payment: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (?Borrower?), agrees to pay to Lender or his or her registered assigns (the ?Holder?) the Principa |
|
| May 13, 2022 |
Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update Exhibit 99.1 Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update Torrance CA, May 13, 2022 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three months ended March 31, 2022 and provided a business update. Recent Highlights ? April 202 |
|
| May 13, 2022 |
Promissory Note dated January 18, 2022 issued to Soomi Niihara Exhibit 10.1 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $300,000.00Loan Date: January 18, 2022 Currency:U.S. dollarsTerm: NA Interest Rate:12% per yearLoan Due Date: Due on demand Interest Payment Period: Interest is payable upon Loan Due Date Lender: Soomi Niihara FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 |
|
| March 31, 2022 |
Promissory Note dated December 7, 2021 issued by registrant to Soomi Niihara. EXHIBIT 10.26 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $700,473.18Loan Date: December 7, 2021 Currency:U.S. dollarsTerm: NA Interest Rate:12% per yearLoan Due Date: Due on demand Interest Payment Period: Interest is payable upon Loan Due Date Lender: Soomi Niihara FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 |
|
| March 31, 2022 |
EXHIBIT 10.21 AMENDMENT NO. 1 TO LOAN AGREEMENT This Amendment No. 1 to Loan Agreement (this ?Amendment?) is made and entered into on January 5, 2022, by and between Emmaus Life Sciences, Inc. (?Lender?) and EJ Holdings, Inc. (?Borrower?) and amends that certain Loan Agreement dated October 28, 2020 (the ?Original Agreement?) as follows: 1.Defined Terms. Capitalized terms used but not otherwise de |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmaus Life Sciences, Inc |
|
| March 31, 2022 |
Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update Exhibit 99.1 Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update Torrance CA, March 31, 2022 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the year ended December 31, 2021 and an update on recent activities. Recent Highlights ? March 2022: |
|
| March 31, 2022 |
Specimen Common Stock Certificate. EXHIBIT 4.1 UMBER EMM [LOGO] SHARES SPECIMEN COMMON STOCK INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SEE REVERSE FOR CERTAIN DEFINITIONS FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF $0.001 PAR VALUE EACH OF EMMAUS LIFE SCIENCES, INC.transferable on the books of the Corporation in person or by attorney upon surrender of this certificate duly endorsed or assigned. This certifica |
|
| March 31, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi |
|
| March 31, 2022 |
License Agreement between Kainos Medicine, Inc. and Emmaus Life Sciences, Inc. EXHIBIT 10.22 License Agreement This License Agreement (this "Agreement"), effective as of October 6, 2021 (the "Effective Date"), is made by and between Kainos Medicine, Inc., a corporation organized and existing under the laws of the Republic of Korea, with offices located at 3F, 29, Dunchon-daero 514 beon-gil, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea ("Licensor"), and Emmaus Life |
|
| February 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) Emmaus Life Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29137T101 (CUSIP Number) Yutaka Niihara, M.D., M.P.H. 21250 Hawthorne Boulevard, Suite 800 Torrance, California 90503 (310) 214-0065 (Name, |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss |
|
| December 30, 2021 |
As filed with the Securities and Exchange Commission on December 30, 2021 As filed with the Securities and Exchange Commission on December 30, 2021 Registration No. |
|
| December 30, 2021 |
Form of Non-Qualified Stock Option Agreement under 2021 Stock Incentive Plan (Non-Director Grantee) Exhibit 4.4 EMMAUS LIFE SCIENCES, INC. 2021 STOCK INCENTIVE PLAN FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT (NON-DIRECTOR GRANTEE) 1. Grant of Option. Emmaus Life Sciences, Inc., a Delaware corporation (the ?Company?), grants to (the ?Grantee?), effective , 202 (the ?Grant Date?), an option (the ?Option?) to purchase an aggregate of up to shares (the ?Shares?) of the Company?s common stock, par |
|
| December 30, 2021 |
Form of Incentive Stock Option Agreement under 2021 Stock Incentive Plan Exhibit 4.2 EMMAUS LIFE SCIENCES, INC. 2021 STOCK INCENTIVE PLAN FORM OF INCENTIVE STOCK OPTION AGREEMENT 1. Grant of Option. Emmaus Life Sciences, Inc., a Delaware corporation (the ?Company?), grants to (the ?Grantee?), effective , 202 (the ?Grant Date?), an option (the ?Option?) to purchase an aggregate of up to shares (the ?Shares?) of the Company?s common stock, par value $0.001 per share (?Co |
|
| December 30, 2021 |
Exhibit 4.3 EMMAUS LIFE SCIENCES, INC. 2021 STOCK INCENTIVE PLAN FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT (NON-EMPLOYEE DIRECTOR GRANTEE) 1. Grant of Option. Emmaus Life Sciences, Inc., a Delaware corporation (the ?Company?), grants to (the ?Grantee?), effective , 202 (the ?Grant Date?), an option (the ?Option?) to purchase an aggregate of up to shares (the ?Shares?) of the Company?s common st |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Emmaus Life Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29137T101 (CUSIP Number) Yutaka Niihara, M.D., M.P.H. 21250 Hawthorne Boulevard, Suite 800 Torrance, California 90503 (310) 214-0065 (Name, |
|
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2021 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCE |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? ? ? ? ? Filed by a Party other than the Registrant ? ? ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| October 12, 2021 |
Exhibit 99.1 Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine Agreement Expands on the Companies? Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies TORRANCE, Calif., October 12, 2021- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle |
|
| October 12, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2021 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commiss |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? ? ? ? ? Filed by a Party other than the Registrant ? ? ?? Check the appropriate box: ? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rul |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, I |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, IN |
|
| September 1, 2021 |
Promissory Note dated April 24, 2021 issued by registrant to Eastwind, Ltd. Exhibit 10.1 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: US$1,500,000Loan Date: 04/24/2021 Currency:US dollarsTerm: Two years Interest Rate:11.0% per yearLoan Due Date: 04/24/2023 Interest Payment Period: Interest is payable annually Lender: Eastwind ltd. FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800, Torrance, |
|
| September 1, 2021 |
Promissory Note dated February 17, 2021 issued by registrant to Shigeru Matsuda. Exhibit 10.2 EMMAUS MEDICAL JAPAN Promissory Note Principal Amount: JPY101,687,488Loan Date: 02/17/2021 Currency:Japanese YenTerm: 2 Years Interest Rate:11.0%Loan Due Date: Due on demand Interest Payment Period: Interest is payable annually Lender: Shigeru Matsuda FOR VALUE RECEIVED, Emmaus Medical, Japan, a Japanese corporation, located at 2-20-11 Hongo Bunkyo-ku 113-0033 Tokyo Japan (?Borrower?) |
|
| September 1, 2021 |
Promissory Note dated May 26, 2021 issued by registrant to Shigeru Matsuda. Exhibit 10.2 EMMAUS MEDICAL JAPAN Promissory Note Principal Amount: JPY74,420,000Loan Date: 05/26/2021 Currency:Japanese YenTerm: 2 Years Interest Rate:11.0%Loan Due Date: Due on demand Interest Payment Period: Interest is payable annually Lender: Shigeru Matsuda FOR VALUE RECEIVED, Emmaus Medical, Japan, a Japanese corporation, located at 2-20-11 Hongo Bunkyo-ku 113-0033 Tokyo Japan (?Borrower?) |
|
| September 1, 2021 |
Promissory Note dated January 20, 2021 issued by registrant to Soomi Niihara Exhibit 10.1 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: $700,000.00Loan Date: January 20, 2021 Currency:U.S. dollarsTerm: NA Interest Rate:12% per yearLoan Due Date: Due on demand Interest Payment Period: Interest is payable upon Loan Due Date Lender: Soomi Niihara FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 |
|
| August 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q i UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIEN |
|
| August 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q i UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, |
|
| August 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIENCES, I |
|
| August 26, 2021 |
Exhibit 10.1 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: Loan Date: Currency:U.S. dollarsTerm: Interest Rate:Loan Due Date: Interest Payment Period: Interest is payable upon Loan Due Date Lender: FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800 Torrance, CA 90503 (?Borrower?) agrees to pay to Lender or her register |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi |
|
| August 10, 2021 |
Exhibit 99.1 Emmaus Life Sciences Provides SEC Reporting Update 2020 Financial Statements Restated to Reflect Increase in Net Income Attributable to Change in Equity Method Investment in Japanese Affiliate Amended and Restated Form 10-K Includes Complete Restated Financial Statements and Currently Dated, Unqualified Audit Report Torrance CA, August 10, 2021 - Emmaus Life Sciences, Inc. (OTC: EMMA) |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmau |
|
| July 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Emmaus Life Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29137T101 (CUSIP Number) Yutaka Niihara, M.D., M.P.H. 21250 Hawthorne Boulevard, Suite 800 Torrance, California 90503 (310) 214-0065 (Name, |
|
| May 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission |
|
| May 19, 2021 |
EX-99.1 2 ea141356ex99-1emmauslife.htm LETTER DATED MAY 19, 2020 FROM BAKER TILLY US, LLP Exhibit 99.1 Baker Tilly US, LLP 3655 Nobel Dr; Ste 300 San Diego, CA 92122 United States of America T: +1 (858) 597 4100 F: +1 (858) 597 4111 bakertilly.com May 19, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Emmaus Life S |
|
| May 17, 2021 |
SEC File Number: 001-35527 CUSIP Number: 29137T101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 4, 2021 |
Exhibit 10.38 EMMAUS LIFE SCIENCES, INC. AMENDMENT NO. 3 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 3 to Convertible Promissory Note (this ?Amendment?) is made and entered into as of June 15, 2020 by and between EMI Holding, Inc., a Delaware corporation (formerly known as Emmaus Life Sciences, Inc and herein ?Borrower? or the ?Company?), and the undersigned holder or its registered assigns |
|
| May 4, 2021 |
Contingent Common Stock Purchase Warrant Exhibit 4.24 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATIO |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35527 Emmaus Life Sciences, Inc |
|
| May 4, 2021 |
Exhibit 10.37 EMI HOLDING, INC. AMENDMENT NO. 2 TO CONVERTIBLE PROMISSORY NOTE This Amendment No. 2 to Convertible Promissory Note (this ?Amendment?) is made and entered into as of January 15, 2020 by and between EMI Holding, Inc., a Delaware corporation (formerly known as Emmaus Life Sciences, Inc and herein ?Borrower? or the ?Company?), and the undersigned holder (the ?Holder?) of the Convertibl |
|
| May 4, 2021 |
Form of July 31, 2020 Common Stock Purchase Warrants EXHIBIT 4.25 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 4, 2021 |
Form of October 8, 2020 Common Stock Purchase Warrants EX-4.27 4 emma-ex427338.htm EX-4.27 Exhibit 4.27 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EX |
|
| March 31, 2021 |
SEC File Number: 001-35527 CUSIP Number: 29137T101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2021 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| February 22, 2021 |
Guaranty dated December 9, 2020 by Emmaus Life Sciences, Inc. in favor or Prestige Capital, Inc. Exhibit 10.2 GUARANTY DATE: December 9, 2020 Prestige Capital Finance, LLC 400 Kelby Street 10th Floor Fort Lee, New Jersey 07024 To induce Prestige Capital Finance, LLC (?Prestige?) to make advances or other financial accommodations to Emmaus Medical, Inc. (?Client?), now or in the future, and with full knowledge that said advances or other financial accommodations would not be made without this |
|
| February 22, 2021 |
Exhibit 10.3 GUARANTY Emmaus Life Sciences, Inc., a Delaware corporation (?Guarantor?), as direct or indirect parent corporation of EMI Holding, Inc., a Delaware corporation (the ?Company?), does hereby unconditionally and irrevocably guarantee to each of the holders (each, a ?Holder? and collectively, the ?Holders?) of the Company?s Amended and Restated 10% Senior Secured Convertible Debentures D |
|
| February 22, 2021 |
EX-10.1 2 ea135022ex10-1emmauslife.htm PURCHASE AND SALE AGREEMENT DATED , 2021 BETWEEN EMMAUS MEDICAL, INC. AND PRESTIGE CAPITAL FINANCE, LLC Exhibit 10.1 Prestige Capital Finance, LLC 400 KELBY STREET, 10TH FLOOR, FORT LEE, NEW JERSEY 07024 (201) 944-4455 Purchase and Sale Agreement (“Agreement”) 1. ASSIGNMENT. PRESTIGE CAPITAL FINANCE, LLC (“Prestige”) hereby buys and EMMAUS MEDICAL, INC. (“Sel |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis |
|
| February 16, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of February 8, 2021, between Emmaus Life Sciences, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and cond |
|
| February 16, 2021 |
Exhibit 10.2 TRANSFER RESTRICTION AND VOTING AGREEMENT This TRANSFER RESTRICTION AND VOTING Agreement (this ?Agreement?) is made and entered into as of February 8, 2021 by and among between Emmaus Life Sciences, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the purchaser signature pages hereto (each, including its successors and permitted assigns, the ?Purchaser?). |
|
| January 25, 2021 |
EX-10.26 8 emma-ex10261513.htm EX-10.26 Exhibit 10.26 Amendment for Distribution Agreement on June 15, 2017 between Emmaus Life Sciences Inc. and Telcon Inc. Emmaus Life Sciences Inc.와 Telcon Inc.는 2017년 6월15일 체결된 Distribution Agreement 중 하기와 같이 내용을 수정 또는 추가함을 합의 한다. Emmaus Life Sciences Inc. and Telcon Inc. agree to amend or add to the following content in the Distribution Agreement on June 15, 2 |
|
| January 25, 2021 |
Specimen Common Stock Certificate. Exhibit 4.1 NUMBER EMM [LOGO] SHARES SPECIMEN COMMON STOCK INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SEE REVERSE FOR CERTAIN DEFINITIONS FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF $0.001 PAR VALUE EACH OF EMMAUS LIFE SCIENCES, INC.transferable on the books of the Corporation in person or by attorney upon surrender of this certificate duly endorsed or assigned. This certific |
|
| January 25, 2021 |
Exhibit 10.35 매도청구권(Call Option-콜옵션) 계약서 Right to Sell (Call Option) Agreement 다음 당사자들은 2020년 9월 28일 다음과 같이 매도청구권(Call Option-콜옵션) 계약(이하 “본 계약”)을 체결한다. This “right to sell(Call Option) agreement” (hereinafter “this agreement”) is executed on September 28, 2020 between the following parties. 1. 발행회사 Issuer 주식회사 텔콘알에프제약 Telcon RF Pharmaceutical, Inc. 대표이사: 김 지 훈 Ji Hoon Kim 주 소: 경기도 용인시 기흥구 공세로 54 ( |
|
| January 25, 2021 |
Exhibit 10.34 주식회사 텔콘알에프제약 제15회 무기명식 이권부 무보증 사모 전환사채 인수계약서 Telcon RF Pharmaceutical, Inc. 15th Bearer-type Interest Purchase Agreement for Unsecured Private Equity Convertible Bonds 발행금액 : 금 삼백억원 (\30,000,000,000) Principal Amount: KRW 30,000,000,000 2020. 09. 28. September 28, 2020 [발행회사] 주식회사 텔콘알에프제약 Issuer: Telcon RF Pharmaceutical, Inc. [인수인] Emmaus Life Sciences, Inc. (엠마우스생명과학) Purchaser: Em |
|
| January 25, 2021 |
Exhibit 10.30 합 의 서(Agreement) 본 합의서는 대한민국에 소재한 1) 주식회사 텔콘알에프제약(구 주식회사 텔콘, 이하 “텔콘”) 및 미합중국에 소재한 2) Emmaus Life Sciences, Inc. (이하 “엠마우스”)간에 2019. 12. 23. 체결되었다. 텔콘 및 엠마우스(이하 총칭하여 “당사자들”)는 아래와 같이 본 합의서의 내용에 대하여 합의한다. This agreement is executed on December 23, 2019 between 1) Telcon RF Pharmaceutical, Inc. (formerly Telcon Co., Ltd. And herein “Telcon”) in Republic of Korea and 2)Emmaus Life Science |
|
| January 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001‑35527 Emmaus Life Sciences, Inc |
|
| January 25, 2021 |
Exhibit 10.28 API Supply Agreement This Agreement (this “Agreement”), is made and entered into this 16 day of 6, 2017 (the “Effective Date”) by and between Emmaus Life Sciences, Inc., a Delaware corporation with offices at 21250 Hawthorne Blvd., Suite 800, Torrance, California 90503, the United States of America (hereinafter called "Manufacturer") and Telcon Inc., Korea corporation ("Supplier"), w |
|
| January 25, 2021 |
EX-10.37 16 emma-ex10371629.htm EX-10.37 Exhibit 10.37 CREDIT ACCESS AND LOAN AGREEMENT THIS CREDIT ACCESS AND LOAN AGREEMENT (this “Agreement”) is made and entered into on January 10, 2020 by and between Yutaka Niihara, M.D., M.P.H. (“Lender”) and Emmaus Life Sciences, Inc., a Delaware corporation (“Emmaus”), with reference to the following facts: RECITALS: Lender is the Chairman of the Board, Ch |
|
| January 25, 2021 |
Exhibit 10.29 추 가 합 의 서 ADDITIONAL AGREEMENT 본 추가합의서는 대한민국에 소재한 1) [주식회사 에버코어인베스트먼트홀딩스(구 텔콘홀딩스(주))(이하 “에버코어”)], 2) 주식회사 텔콘알에프제약(구 주식회사 텔콘, 이하 “텔콘”) 및 미합중국에 소재한 3) Emmaus Life Sciences, Inc. (이하 “엠마우 스”)간에 2018. 7. 2. 체결되었다. This ADDITIONAL AGREEMENT (this “Agreement”) is made as of July 2, 2018 by and among (1) Evercore Investment Holdings Co., Ltd. (formerly Telcon Holdings Co. Ltd., “Evercore”), |
|
| January 25, 2021 |
Promissory Note dated April 24, 2019. Exhibit 10.11 EMMAUS LIFE SCIENCES, INC. Promissory Note Principal Amount: US$1,500,000Loan Date: 04/24/2019 Currency:US dollarsTerm: Two years Interest Rate:11.0% per yearLoan Due Date: Due on demand Interest Payment Period: Interest is payable annually Lender: Eastwind ltd. FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800, Torran |
|
| January 25, 2021 |
EX-10.23 6 emma-ex1023941.htm EX-10.23 Exhibit 10.23 EXHIBIT C FORM OF THIRD AMENDMENT TO OFFICE LEASE AGREEMENT THIRD AMENDMENT TO OFFICE LEASE AGREEMENT THIS THIRD AMENDMENT TO OFFICE LEASE AGREEMENT (this "Second Amendment") is made and entered into effective as of September 10, 2019 (the "Effective Date"), by and between RREF II PACIFIC CENTER LLC, a Delaware limited liability company ("Landlo |
|
| January 25, 2021 |
EX-10.27 9 emma-ex10273369.htm EX-10.27 Confidential Document Exhibit 10.27 Raw Material Supply Agreement Pharmaceutical Grade L-glutamine (PGLG) Emmaus Life Sciences, Inc. Telcon Inc. 1 / 7 Confidential Document Raw Maerial Supply Agreement This Agreement (this “Agreement”), is made by and between Emmaus Life Sciences. Inc. (hereinafter called "Manufacturer") and Telcon Inc. ("Supplier") in order |
|
| January 25, 2021 |
Exhibit 10.33 확 약 서 (Letter of Commitment) Emmaus Life Sciences, Inc. (이하 “엠마우스)는 나스닥(또는 NYSE American)에 상장을 진행 중에 있으며, 상장을 위한 순수자본요건을 충족하기 위하여 엠마우스가 보유한 주식회사 텔콘알에프제약(구 주식회사 텔콘, 이하 “텔콘”) 발행 주식을 처분하기를 희망하는 바, 아래의 사항을 당사자들은 각각 확약하기로 한다. Emmaus Life Sciences, Inc. (“Emmaus”) is in the process of seeking to up-list its common stock on NASDAQ (or NYSE American) and wishes to liquidate the shares of Tel |
|
| January 25, 2021 |
Exhibit 10.25 Distributor Agreement This Agreement (this “Agreement”), is made and entered into this 15day of 6, 2017 (the “Effective Date”) by and between Emmaus Life Sciences, Inc., a Delaware corporation with offices at 21250 Hawthorne Blvd., Suite 800, Torrance, California 90503, the United States of America (hereinafter called "Manufacturer") and Telcon Inc., Korea corporation ("Distributor") |
|
| January 25, 2021 |
Promissory Note dated May 26, 2019. Exhibit 10.12 EMMAUS MEDICAL JAPAN Promissory Note Principal Amount: JPY61,000,000Loan Date: 05/26/2019 Currency:Japanese YenTerm: 2 Years Interest Rate:11.0%Loan Due Date: Due on demand Interest Payment Period: Interest is payable annually Lender: Shigeru Matsuda FOR VALUE RECEIVED, Emmaus Medical, Japan, a Japanese corporation, located at 2-20-11 Hongo Bunkyo-ku 113-0033 Tokyo Japan (“Borrower”) |
|
| January 25, 2021 |
Exhibit 21.1 List of Subsidiaries Name Place of incorporation EMI Holding, Inc. Delaware Emmaus Medical, Inc. Delaware Emmaus Medical Japan, Inc. Japan Newfield Nutrition Corporation Delaware Emmaus Medical Europe Limited United Kingdom Emmaus Medical Europe Limited Ireland Emmaus Life Sciences, Co. Ltd. Korea EJ Holdings, Inc. (40% consolidated under the Variable Interest Entity Model) Japan |
|
| January 25, 2021 |
Restated Certificate of Incorporation. EX-3.1 2 emma-ex3112.htm EX-3.1 Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF EMMAUS LIFE SCIENCES, INC. (Originally incorporated on March 20, 1987 under the name of AGE RESEARCH, INC.) ARTICLE I The name of the corporation is Emmaus Life Sciences, Inc. (the “Corporation”). ARTICLE II The registered office of the Corporation in the State of Delaware is 9 E. Loockerman Street, Suite 311, Dov |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis |
|
| November 13, 2020 |
Loan Agreement Dated October 28, 2020 Between Emmaus Life Sciences, Inc. and EJ Holdings, Inc EX-10.1 2 ea129796ex10-1emmauslife.htm LOAN AGREEMENT DATED OCTOBER 28, 2020 BETWEEN EMMAUS LIFE SCIENCES, INC. AND EJ HOLDINGS, INC Exhibit 10.1 Loan Agreement Emmaus Life Sciences, Inc. (hereafter “Lender”) and EJ Holdings, Inc. (hereafter “Borrower”) make and enter into this this Loan Agreement (hereafter this “Agreement”) as below. Article 1 (Loan Agreement) The Lender has loaned and agrees to |
|
| November 5, 2020 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis |
|
| November 5, 2020 |
Letter dated November 4, 2020 from Squar Milner LLP to the Securities and Exchange Commission Exhibit 16.1 November 4, 2020 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentleman: We are the former independent registered public accounting firm for Emmaus Life Sciences, Inc. (the “Company”). We have read the Company’s disclosure set forth in Item 4.01 “Changes in Registrant’s Certifying Accountant” of the Company’s Current Report on Form 8-K dated |
|
| October 29, 2020 |
Exhibit 99.1 Hope Delivered : Changing Lives Today The first treatment approved by the FDA for Sickle Cell Disease in nearly 20 years Informational Meeting of Stockholders September 17, 2020 Safe Harbor Statement This presentation by Emmaus Life Sciences, Inc . (“Emmaus” or the “Company”) contains forward - looking statements made pursuant to the safe harbor provisions of the Private Securities Li |
|
| October 29, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis |
|
| October 20, 2020 |
Entry into a Material Definitive Agreement - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Comm |
|
| October 8, 2020 |
Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of in |
|
| September 25, 2020 |
Financial Statements and Exhibits - AMENDMENT NO. 1 TO FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of |
|
| September 25, 2020 |
Letter dated September 24, 2020 from BDO USA, LLP to the Securities and Exchange Commission Exhibit 16.1 Tel: (310) 557-0300 Fax: (310) 557-1777 www.bdo.com 515 S Flower St, 47th Floor Los Angeles, CA 90071 September 24, 2020 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on September 10, 2020, filed by our former client, Emmaus Life Sciences, Inc. (“Compan |
|
| September 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Comm |
|
| September 24, 2020 |
Form of September 22, 2020 Common Stock Purchase Warrants Exhibit 10.1 SECURITIES AMENDMENT AGREEMENT THIS SECURITIES AMENDMENT AGREEMENT (this “Agreement”), dated as of September 22, 2020, is entered into by and among EMI Holding, Inc, a Delaware corporation (the “Company”), Emmaus Life Sciences, Inc., a Delaware corporation and the parent company of EMI (“Emmaus”), and the parties identified as “Holders” on the signature page hereto (the “Holders”). WH |
|
| September 17, 2020 |
Changes in Registrant's Certifying Accountant - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Comm |
|
| September 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| July 31, 2020 |
Emmaus Life Sciences Provides Additional Operational and OTC Markets Updates Exhibit 99.1 Emmaus Life Sciences Provides Additional Operational and OTC Markets Updates Torrance CA, July 31, 2020 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, provided today additional operational updates for the year ended December 31, 2019 as well as operational updates for the quarters ended March 31 and June 30, 2020 in advance of the filing of its |
|
| July 31, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissio |
|
| July 8, 2020 |
Emmaus Life Sciences to Restate Previously Issued Financial Statements EX-99.1 2 ea123925ex99-1emmauslife.htm PRESS RELEASE DATED JULY 8, 2020 EXHIBIT 99.1 Emmaus Life Sciences to Restate Previously Issued Financial Statements Torrance CA, July 8, 2020 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today announced it will be restating its previously issued audited consolidated financial statements for the twelve months ended De |
|
| July 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commission |
|
| May 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-15327 FORM 12b-25 CUSIP NUMBER Not applicable NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Re |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-15327 FORM 12b-25 CUSIP NUMBER Not applicable NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2019 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition |
|
| April 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis |
|
| April 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Emmaus Life Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29137T101 (CUSIP Number) Yutaka Niihara, M.D., M.P.H. 21250 Hawthorne Boulevard, Suite 800 Torrance, California 90503 (310) 214-0065 (Name, |
|
| March 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi |
|
| March 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commissi |
|
| March 3, 2020 |
Exhibit 10.1 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 28, 2020, is entered into by and between EMMAUS LIFE SCIENCES, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used he |
|
| March 3, 2020 |
Up to $25,000,000 of Common Stock 415,743 Shares of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus dated June 8, 2018) Registration No. |
|
| March 3, 2020 |
Exhibit 99.1 Emmaus Life Sciences Announces Equity Purchase Agreement for up to $25 Million with Lincoln Park Capital Torrance CA, March 3, 2020 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the execution of a purchase agreement for up to $25 million of common stock with Lincoln Park Capital Fund, LLC (“LPC”), a long-only Chicago-based insti |
|
| March 3, 2020 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| March 3, 2020 |
Exhibit 1.1 Execution Version PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of February 28, 2020 (the “Execution Date”), by and between EMMAUS LIFE SCIENCES, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined herein are defined in S |
|
| February 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| February 27, 2020 |
Exhibit 10.1 SECURITIES AMENDMENT AGREEMENT THIS SECURITIES AMENDMENT AGREEMENT (this “Agreement”), dated as February 21, 2020, is entered into by and among EMI Holding, Inc. (formerly known as “Emmaus Life Sciences, Inc.”), a Delaware corporation (the “Company”), Emmaus Life Sciences, Inc.,(formerly known as “MYnd Analytics, Inc.”), a Delaware corporation and the parent company of EMI (“Emmaus”) |
|
| January 6, 2020 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2019 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| January 6, 2020 |
Letter dated January 6, 2020 from Marcum LLP to the Securities and Exchange Commission. EX-16.1 2 f8k123019ex16-1emmauslife.htm LETTER DATED JANUARY 6, 2020 FROM MARCUM LLP TO THE SECURITIES AND EXCHANGE COMMISSION Exhibit 16.1 January 6, 2020 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Emmaus Life Sciences, Inc. under Item 4.01 of its Form 8-K dated January 6, 2020. We agree with the statements concern |
|
| December 23, 2019 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2019 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| November 13, 2019 |
i UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-35527 EMMAUS LIFE SCIEN |
|
| November 13, 2019 |
Exhibit 10.7 Loan Agreement Emmaus Life Sciences, Inc. (hereafter I "Lender'') and EJ Holdings Inc. (hereafter "Borrower") make and enter into this this Loan Agreement (hereafter this "Agreement") as below. Article 1(Loan Agreement) The Lender agrees to loan to Borrower the loan amount (hereafter the "Loan") according to the articles of this Agreement on the terms listed below. 1) Loan amount: 2) |
|
| November 12, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| November 12, 2019 |
EX-99.1 2 f8k1119ex99-1emmauslife.htm NOVEMBER 12, 2019 PRESS RELEASE Exhibit 99.1 Emmaus Life Sciences Reports 2019 Third Quarter Financial Results - Net Revenues Increased 25% Year-Over-Year, Company Opens and Expands Class of Trade with Community Hematologists and Correctional Facilities - Torrance CA, November 12, 2019 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease |
|
| October 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2019 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis |
|
| October 29, 2019 |
Exhibit 99.1 Emmaus Life Sciences Announces Equity Investment from a Corporate Investor - Company Enters Into Common Stock Purchase Agreement with Vivozon, Inc. - Torrance CA, October 29, 2019 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported that Vivozon, Inc. has executed a stock purchase agreement for the purchase of 800,000 shares of Emmaus c |
|
| October 25, 2019 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-223203 PROSPECTUS SUPPLEMENT (To Prospectus dated June 8, 2018) 800,000 Shares Common Stock We are offering 800,000 shares of our common stock pursuant to a stock purchase agreement between us and the investor dated as of October 25, 2019. The shares of common stock are being offered directly to investor without the services of a placement agen |
|
| October 24, 2019 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2019 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis |
|
| October 24, 2019 |
Letter dated October 24, 2019 from SingerLewak LLP to the Securities and Exchange Commission. Exhibit 16.1 October 24, 2019 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We have read Emmaus Life Sciences, Inc.’s (formerly known as MYnd Analytics, Inc.) statements included under Item 4.01 of its Form 8-K filed on the October 24, 2919 and we agree with such statements concerning our firm. |
|
| October 11, 2019 |
EX-99.1 2 f8k101119ex99-1emmauslife.htm PRESS RELEASE Exhibit 99.1 Emmaus Life Sciences Reports Preliminary Gross Sales for the Three Months Ended September 30, 2019 - Company Reports Highest Gross Sales Month of 2019 and Total Gross Sales of $7.0 Achieved in the Third Quarter - Torrance CA, October 11, 2019 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease (SCD) treatmen |
|
| October 11, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2019 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commis |
|
| October 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2019 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Comm |
|
| September 30, 2019 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2019 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Comm |
|
| September 11, 2019 |
MYAN / MYnd Analytics, Inc. S-8 - - REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on September 11, 2019 Registration No. |
|
| September 10, 2019 |
EX-99.1 2 f8k090919ex99-1emmaus.htm PRESS RELEASE DATED SEPTEMBER 10, 2019 Exhibit 99.1 Emmaus Life Sciences to be Delisted from Nasdaq Stock Market Following Hearing - Company Committed to Listing on Major Exchange - Torrance CA, September 10, 2019 - Emmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, announced today that it was informed yesterday that the Nasdaq |
|
| September 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2019 Emmaus Life Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35527 87-0419387 (State or other jurisdiction of incorporation) (Commi |
|
| September 5, 2019 |
MYAN / MYnd Analytics, Inc. / Jjbe 123 Llc Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* EMMAUS LIFE SCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 share (Title of Class of Securities) 29137T101 (CUSIP Number) July 17, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| August 26, 2019 |
MYAN / MYnd Analytics, Inc. / Telcon Rf Pharmaceutical Inc. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENT FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 Emmaus Life Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 29137T 101 (CUSIP |
|
| August 23, 2019 |
MYND / MYnd Analytics, Inc. / Glaser Jonathan M - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1)* Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENT FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 Emmaus Life Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securitie |
|
| August 23, 2019 |
Joint Filing Agreement attached as Exhibit 99.1 EX-99.1 2 sc13g0819a1ex99-1emmaus.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint fili |
|
| August 14, 2019 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS EX-99.2 4 emma-ex99248.htm EX-99.2 Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial statements present the pro forma financial position and results of operations of (1) MYnd Analytics, Inc. (now known as Emmaus Life Sciences, Inc. and herein “MYnd”) based on the historical consolidated financial statements of MY |
